Merck Serono launches €1m research grant for multiple sclerosis innovation

Annual award aims to improve understanding of the condition to drive medical breakthroughs

Merck Serono, the biopharmaceutical division of Merck KGaA, has initiated a new global research award to improve understanding of multiple sclerosis.

The Grant for Multiple Sclerosis Innovation programme will award up to €1m annually to fund innovative research into multiple sclerosis (MS) by academic researchers. Potential research topics that could be funded include MS pathogenesis, predictive markers for treatment response and potential new treatments.

‘We are committed to driving innovative research to further contribute to our understanding of the disease and ultimately lead to new medical breakthroughs in multiple sclerosis,’ said Annalisa Jenkins, head of global drug development and medical for Merck Serono. ‘While tremendous progress has been made over the years, we must continue to search for answers to important scientific questions in the field.’

This grant complements other existing programs like Merck Serono's collaboration with the National Multiple Sclerosis Society, the FastForward collaborative fund.

The funds from the Grant for Multiple Sclerosis Innovation will be awarded by EMD Serono for projects based in the US and Canada and by Merck Serono to those based in the rest of the world.

Researchers can submit their project proposals via the programme's website, www.grantformultiplesclerosisinnovation.org.

Companies